This study therefore assessed the relationship between HIV-1-circulating genotypes and drug-resistant mutations among IDUs. Subtype A has been subdivided into A 1, A 2, A 3, A 4, A 5, and A 6, while subtype F has been subdivided into F 1 and F 2. The M group is subdivided further into clades, called subtypes, which are also given letters ranging from A to K. HIV type 1 is divided into groups M, N, O, and P, more than 90% of HIV infections are derived from HIV-1 group M, and the rest are minor groups. Extensive genetic heterogeneity is driven by several factors, such as the lack of proofreading ability of the reverse transcriptase (RT), the rapid turnover of HIV-1 in vivo, host-selective immune pressures, leading to drug resistance selection pressure, and recombination events during replication. HIV-1 infection is highly diverse with the circulation of subtypes A (50–80%), D (10–20%), and C (5–15%) and multiple recombinants (10–20%). Studies in Kenya have reported the occurrence of HIV drug resistance upon ART failure in Mombasa, Mombasa and Nairobi as part of a multisite African study, and Burnt Forest, a rural Academic Model Providing Access to Healthcare (AMPATH) clinic. These mutant variants have become increasingly widespread, in drug-treated and untreated individuals infected with HIV, and have compromised the therapeutic options of drug-naïve infected people. However, limited studies have been done on the high-risk group such as injecting drug users (IDUs). Drug resistance testing and monitoring of HIV subtypes can improve treatment outcomes in infected individuals. Indeed, transmitted drug resistance generally leads to a delay in virologic suppression and results in an increased risk of treatment failure. The success of these drug regimens is being challenged by the emergence of drug-resistant mutations. The introduction of highly active antiretroviral therapy (HAART) in 1996 has resulted in improved treatment outcome and survival rate in human immunodeficiency virus-1 (HIV-1) infected patients. In addition, further characterization of DRMs including all the relevant clinical parameters among the larger population of IDUs is critical for effective drug resistance surveillance. Due to the large proportion of drug resistance across all HIV-1 subtypes, surveillance and behavioral studies need to be explored as IDUs may be spreading the drug resistance to the general population. Stanford HIV Drug Resistance Database was used to interpret DRMs. This study therefore determined the association between HIV-1 genotypes and DRMs among the 200 IDUs. Nevertheless, few studies have investigated the relationship between DRMs and HIV-1 subtypes among HIV-positive injecting drug users (IDUs). Installer Size: 225 MB Download Links : Gene Codes Sequencher v5.4.HIV-1 genetic diversity results into the development of widespread drug-resistant mutations (DRMs) for the first-line retroviral therapy. Here are some key features of “Sequencher”: Come see whySequencher has been published in tens of thousands of researcharticles, and peer-reviewed journals. Everything from trimming reads, customassembly and alignment algorithms, variation tables, summaryreports, annotation the list goes on and on. With an easy to useinterface that has been honed over 25 years, first time users willfeel like a pro in minutes. Sequencher’s extensiveSanger analysis features are the foundation it was built upon.Customizable from start to finish there is no other program thatoffers you as much power as Sequencher. Sequencher can easily generate unique visualizations of yourRNA-Seq data with custom plots and charts giving youpublication-ready graphics in seconds. Sequencher has integrated the comprehensive Cufflinkssuite for in-depth transcript analysis and differential geneexpression of your RNA-Seq data. Whetherperforming reference-guided alignments, de novo assembly, variantcalling, or SNP analyses, Sequencher has the tools you need to getresults. Sequencher empowers the benchtop scientist bybringing the latest peer-reviewed NGS algorithms out of the commandline and into an intuitive point and click interface.
0 Comments
Leave a Reply. |